![]() |
Philip Greenberg | |
---|---|
![]() Greenberg in 2025 | |
Nationality | American |
Education | |
Known for | T cell receptor T cell therapy |
Scientific career | |
Fields | Hematology |
Institutions | |
Website | Fred Hutch page |
Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. [1] He is a co-founder of Juno Therapeutics. [2] [3] [4]
Greenberg graduated from Washington University in St. Louis with a degree in biology; he received his M.D. in 1971 from SUNY Downstate Medical Center. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Center and the Division of Oncology at the University of Washington, in 1976. [5] His research is focused on T cell adoptive immunotherapy. His group has demonstrated the potential of isolating antigen-specific T cells and growing them to perform in vivo activity against a disease. [6] [7] [8] He has also done work on re-engineering T cells to produce TCR-T that will work for non-leukemia malignancies. [9]
![]() | This section of a biography of a living person needs additional citations for verification .(October 2023) |